IRIS
PORTA, Camillo Guglielmo Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.838
EU - Europa 1.090
AS - Asia 207
SA - Sud America 5
AF - Africa 2
OC - Oceania 1
Totale 5.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.833
SE - Svezia 426
IT - Italia 325
FR - Francia 137
GB - Regno Unito 121
VN - Vietnam 111
IE - Irlanda 36
HK - Hong Kong 29
CN - Cina 20
DE - Germania 15
JP - Giappone 13
BE - Belgio 10
IN - India 8
FI - Finlandia 7
TR - Turchia 7
IR - Iran 4
NL - Olanda 4
CA - Canada 3
LU - Lussemburgo 3
NP - Nepal 3
PK - Pakistan 3
AT - Austria 2
EC - Ecuador 2
KR - Corea 2
SA - Arabia Saudita 2
TN - Tunisia 2
AZ - Azerbaigian 1
BD - Bangladesh 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
CO - Colombia 1
CR - Costa Rica 1
KH - Cambogia 1
MX - Messico 1
NZ - Nuova Zelanda 1
PL - Polonia 1
PS - Palestinian Territory 1
SG - Singapore 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
Totale 5.143
Salva come PNG Salva come JPEG
Città #
Fairfield 652
Cambridge 350
Nyköping 348
Ashburn 327
Woodbridge 264
Seattle 253
Houston 246
Chandler 228
Lawrence 223
Wilmington 221
Bari 208
Roxbury 205
Paris 134
Des Moines 121
Ann Arbor 112
Dong Ket 111
San Diego 85
New York 84
Inglewood 76
London 53
Dublin 36
Hong Kong 28
Princeton 18
Rome 18
New Bedfont 15
Beijing 13
Hounslow 11
Brooklyn 10
Brussels 10
Milan 10
Prescot 10
Hōrai 9
Kilburn 9
Dearborn 7
Helsinki 7
Istanbul 6
Boardman 5
Chicago 5
Los Angeles 5
Norwalk 5
Southwark 5
Bologna 4
Tehran 4
Terlizzi 4
Andria 3
Catania 3
Chiswick 3
Molfetta 3
Naples 3
Pune 3
San Francisco 3
San Mateo 3
Amsterdam 2
Candela 2
Cottage Grove 2
Ferrara 2
Karachi 2
Leawood 2
Luxembourg 2
Monmouth Junction 2
Mountain View 2
Parma 2
Redmond 2
Redwood City 2
Riyadh 2
San Paolo 2
Toronto 2
Varese 2
Venezia 2
Vienna 2
Wandsworth 2
Yangzhou 2
Acton 1
Apodaca 1
Assago 1
Auckland 1
Augusta 1
Bergamo 1
Berlin 1
Bogotá 1
Brandenburg 1
Bratislava 1
Catanzaro 1
Central 1
Clearwater 1
Colwyn Bay 1
Dongjak-gu 1
Düsseldorf 1
Frankfurt am Main 1
Gambettola 1
Giovinazzo 1
Guayaquil 1
Gunzenhausen 1
Hanover 1
Islington 1
Jinan 1
Kumar 1
Kunming 1
Lahore 1
Livorno 1
Totale 4.647
Salva come PNG Salva come JPEG
Nome #
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 105
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 78
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation 73
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma 67
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy 65
Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma 57
Exploring the Spectrum of Kidney Ciliopathies 54
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés 53
Understanding the mechanisms of resistance in EGFR-positive NSCLC: From tissue to liquid biopsy to guide treatment strategy 52
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies 51
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 50
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale 50
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells 48
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial 48
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes 47
Culture in embryonic kidney serum and xeno-free media as renal cell carcinoma and renal cell carcinoma cancer stem cells research model 46
Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer 45
Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance 45
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 45
Hormone signaling pathways as treatment targets in renal cell cancer (Review) 44
The role of tivozanib in advanced renal cell carcinoma therapy 43
Large extracellular vesicles—a new frontier of liquid biopsy in oncology 41
Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art 41
Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review 39
Renin angiotensin system deregulation as renal cancer risk factor (Review) 38
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer 38
Non-melanoma skin cancers: Biological and clinical features 37
Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review 37
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 37
ASSURE vs. S-TRAC: Conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics 36
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 35
Choosing the right cell line for renal cell cancer research 35
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma 35
Steroids in prostate cancer: The jury is still out⋯ and even more confused 35
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials 35
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma 34
Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities 34
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial 34
Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison 33
Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer 33
Opening an onconephrology clinic: Recommendations and basic requirements 33
The role of the cell-cell interactions in cancer progression 33
Toward a genome-based treatment landscape for renal cell carcinoma 33
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial 33
Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model. 33
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas 32
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 32
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: Final results from an expanded-access trial 32
Prognostic Value of 18 F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel 32
The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma 32
Acute Kidney Injury in Cancer Patients 32
The adjuvant treatment of kidney cancer: a multidisciplinary outlook 32
Sunitinib in the treatment of renal cell carcinoma: An update on recent evidence 32
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 32
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 32
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 31
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 31
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial 31
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma 31
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas 31
Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program 31
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial 31
Pazopanib in patients with clear-cell renal cell carcinoma: Seeking the right patient 31
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice 31
Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma 31
Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma 30
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials 30
Targeting stim and Orai proteins as an alternative approach in anticancer therapy 30
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? 30
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 30
Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines 29
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: A systematic review and meta-analysis 29
Transplantation of kidneys with tumors 29
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 29
Glomerular diseases and cancer: evaluation of underlying malignancy 29
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 29
Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts Characterization of the metastatic behaviour and gene expres‐ sion profile (RNAseq) of different melanoma cell lines: a compre‐ hensive in vivo model. 29
1101MO Development of CAR T-cells for future treatment of NETs 29
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 28
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma 28
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 28
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 28
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 27
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 27
Dovitinib (CHIR258, TKI258): Structure, development and preclinical and clinical activity 27
Urea-based cream to prevent sorafenib-induced hand-and-foot skin reaction: Which evidence? 27
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study 27
Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma 27
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 27
Vitamin K effects in human health: new insights beyond bone and cardiovascular health 27
An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy 27
Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma 27
The clonal heterogenicity of circulating tumor cells (CTCs) drives their metastatic potential: a new NOD-SCID melanoma model 27
Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature 26
Comparing comparators: A look at control arms in kidney cancer studies over the years 26
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker? 26
Adjuvant therapy in renal cell carcinoma 26
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents 26
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 26
Insulin-like growth factor-1 signaling in renal cell carcinoma 26
Totale 3.621
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.396
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.396
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202099 0 0 0 10 13 13 13 14 13 7 12 4
2020/20212.515 2 11 10 14 1.075 11 252 545 78 290 60 167
2021/20221.536 275 22 10 17 69 164 24 40 152 151 230 382
2022/20231.229 241 155 140 22 73 143 142 79 153 10 20 51
2023/2024678 46 245 50 42 55 119 26 43 39 12 1 0
Totale 6.057